Gbolahan OB, et al. - In this retrospective study, researchers used the Indiana University pancreatic cancer database to assess trends of chemotherapy use and over-all survival (OS) in patients with recurrent pancreatic ductal adenocarcinoma (PDAC)[rPDAC] after curative therapy. Among 223 cases (51.2%) with rPDAC, chemotherapy was received by 140 patients (63%) and not received by 71 patients (32%). Factors that were related to improved OS in multivariate Cox regression analysis were margin negative resection, peri-operative therapy, radiotherapy and the use of any chemotherapy for rPDAC. In rPDAC, the use of standard approved multi-agent therapy was supported based on evidence generated in this study. These standard combination therapies significantly benefitted patients with median OS comparable to what is seen with treatment for de novo metastatic PDAC.